Open Beta
MetriLume

US marketsCAPR

SEC-sourced researchBeta

CAPR

CAPRICOR THERAPEUTICS, INC.

Company comparison ↗

Data passport

CIK
0001133869
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Nov 16, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 22,270,465.0000 USD; December 2025: 0.0000 USD22.3M USD0 USD0December 2024December 2025
CAPR · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202422,270,465.0000Mar 17, 2026
December 20250.0000Mar 17, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20250.0000-105,043,946.0000-69,811,261.0000355,949,294.000050,157,149.0000Mar 17, 2026
December 202422,270,465.0000-40,467,186.0000-39,995,742.0000170,481,086.000025,018,750.0000Mar 17, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

57/100
Profitability—
Growth0
Balance sheet86
Cash generation—
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$0Jan 1, 2025 – Dec 31, 2025Mar 17, 202610-K
Previous period revenueRevenues$22.27MJan 1, 2024 – Dec 31, 2024Mar 17, 202610-K
Net incomeNetIncomeLoss-$105.04MJan 1, 2025 – Dec 31, 2025Mar 17, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$69.81MJan 1, 2025 – Dec 31, 2025Mar 17, 202610-K
Total assetsAssets$355.95MDec 31, 2025Mar 17, 202610-K
Total liabilitiesLiabilities$50.16MDec 31, 2025Mar 17, 202610-K

New filings

Explore methodology ↗